AbbVie Statistics
Total Valuation
AbbVie has a market cap or net worth of $442.36 billion. The enterprise value is $506.68 billion.
| Market Cap | 442.36B |
| Enterprise Value | 506.68B |
Important Dates
The last earnings date was Friday, July 31, 2026, before market open.
| Earnings Date | Jul 31, 2026 |
| Ex-Dividend Date | Jul 15, 2026 |
Share Statistics
AbbVie has 1.77 billion shares outstanding. The number of shares has increased by 0.03% in one year.
| Current Share Class | 1.77B |
| Shares Outstanding | 1.77B |
| Shares Change (YoY) | +0.03% |
| Shares Change (QoQ) | -0.23% |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 76.27% |
| Float | 1.76B |
Valuation Ratios
The trailing PE ratio is 70.72 and the forward PE ratio is 16.50. AbbVie's PEG ratio is 1.22.
| PE Ratio | 70.72 |
| Forward PE | 16.50 |
| PS Ratio | 6.87 |
| Forward PS | 6.32 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 24.29 |
| P/OCF Ratio | 22.68 |
| PEG Ratio | 1.22 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.47, with an EV/FCF ratio of 27.82.
| EV / Earnings | 80.81 |
| EV / Sales | 7.87 |
| EV / EBITDA | 16.47 |
| EV / EBIT | 22.13 |
| EV / FCF | 27.82 |
Financial Position
The company has a current ratio of 0.81
| Current Ratio | 0.81 |
| Quick Ratio | 0.49 |
| Debt / Equity | n/a |
| Debt / EBITDA | 2.28 |
| Debt / FCF | 3.89 |
| Interest Coverage | 7.85 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 10.51% |
| Return on Invested Capital (ROIC) | 17.70% |
| Return on Capital Employed (ROCE) | 24.49% |
| Weighted Average Cost of Capital (WACC) | 5.41% |
| Revenue Per Employee | $1.13M |
| Profits Per Employee | $110,000 |
| Employee Count | 57,000 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 3.47 |
Taxes
In the past 12 months, AbbVie has paid $2.38 billion in taxes.
| Income Tax | 2.38B |
| Effective Tax Rate | 27.39% |
Stock Price Statistics
The stock price has increased by +21.11% in the last 52 weeks. The beta is 0.28, so AbbVie's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | +21.11% |
| 50-Day Moving Average | 244.97 |
| 200-Day Moving Average | 225.72 |
| Relative Strength Index (RSI) | 52.14 |
| Average Volume (20 Days) | 5,048,263 |
Short Selling Information
The latest short interest is 22.55 million, so 1.28% of the outstanding shares have been sold short.
| Short Interest | 22.55M |
| Short Previous Month | 21.90M |
| Short % of Shares Out | 1.28% |
| Short % of Float | 1.28% |
| Short Ratio (days to cover) | 3.69 |
Income Statement
In the last 12 months, AbbVie had revenue of $64.39 billion and earned $6.27 billion in profits. Earnings per share was $3.54.
| Revenue | 64.39B |
| Gross Profit | 46.87B |
| Operating Income | 22.89B |
| Pretax Income | 8.70B |
| Net Income | 6.27B |
| EBITDA | 30.76B |
| EBIT | 22.89B |
| Earnings Per Share (EPS) | $3.54 |
Balance Sheet
The company has $6.57 billion in cash and $70.89 billion in debt, with a net cash position of -$64.32 billion or -$36.40 per share.
| Cash & Cash Equivalents | 6.57B |
| Total Debt | 70.89B |
| Net Cash | -64.32B |
| Net Cash Per Share | -$36.40 |
| Equity (Book Value) | -5.89B |
| Book Value Per Share | -3.36 |
| Working Capital | -7.97B |
Cash Flow
In the last 12 months, operating cash flow was $19.51 billion and capital expenditures -$1.30 billion, giving a free cash flow of $18.21 billion.
| Operating Cash Flow | 19.51B |
| Capital Expenditures | -1.30B |
| Depreciation & Amortization | 7.87B |
| Net Borrowing | 418.00M |
| Free Cash Flow | 18.21B |
| FCF Per Share | $10.30 |
Margins
Gross margin is 72.79%, with operating and profit margins of 35.56% and 9.80%.
| Gross Margin | 72.79% |
| Operating Margin | 35.56% |
| Pretax Margin | 13.51% |
| Profit Margin | 9.80% |
| EBITDA Margin | 47.78% |
| EBIT Margin | 35.56% |
| FCF Margin | 28.28% |
Dividends & Yields
This stock pays an annual dividend of $6.92, which amounts to a dividend yield of 2.76%.
| Dividend Per Share | $6.92 |
| Dividend Yield | 2.76% |
| Dividend Growth (YoY) | 5.56% |
| Years of Dividend Growth | 54 |
| Payout Ratio | 195.50% |
| Buyback Yield | -0.03% |
| Shareholder Yield | 2.74% |
| Earnings Yield | 1.42% |
| FCF Yield | 4.12% |
Analyst Forecast
The average price target for AbbVie is $276.24, which is 10.35% higher than the current price. The consensus rating is "Buy".
| Price Target | $276.24 |
| Price Target Difference | 10.35% |
| Analyst Consensus | Buy |
| Analyst Count | 31 |
| Revenue Growth Forecast (3Y) | 8.93% |
| EPS Growth Forecast (3Y) | 21.65% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AbbVie has an Altman Z-Score of 2.42 and a Piotroski F-Score of 8. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.42 |
| Piotroski F-Score | 8 |